Nizar Bahlis, MD | Authors


Updated MAIA Trial Data Show Improved Survival for Multiple Myeloma

May 04, 2020

Nizar Bahlis, MD, discusses the findings from the randomized phase III MAIA trial, which evaluated the combination regimen of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in transplant-ineligible patients with multiple myeloma.